Antiangiogenic Tumor Treatment. Noninvasive Monitoring with Contrast Pulse Sequence Imaging for Contrast-Enhanced Grayscale Ultrasound

Academic Radiology

Volumn 17, Issue 5, 2010, Pages 646-651

  Zhou, Jianhua ^a   Zheng, Wei ^a   Cao, Longhui ^a   Liu, Min ^a   Han, Feng ^a   Li, Anhua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

antiangiogenic therapy; contrast pulse sequencing imaging; contrast enhanced ultrasound; Tumor

Indexed keywords

THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOGRAPHY; HISTOLOGY; LIVER CELL CARCINOMA; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; TUMOR NECROSIS; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INFORMATION STORAGE AND RETRIEVAL; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHOSPHOLIPIDS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL PROCESSING, COMPUTER-ASSISTED; SULFUR HEXAFLUORIDE; THALIDOMIDE; TREATMENT OUTCOME; ULTRASONOGRAPHY;

EID: 77950337963     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acra.2010.01.008     Document Type: Article

References (35)

1. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94 (2002) 883-893
2. Padhani A.R., and Neeman M. Challenges for imaging angiogenesis. Br J Radiol 74 (2001) 886-890
3. Lassau M., Chebil M., Chami L., et al. A new functional imaging technique for the early functional evaluation of antiangiogenic treatment: dynamic contrast-enhanced ultrasonography (DCE-US). Targ Oncol 3 (2008) 111-117
4. Kerbel R., and Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2 (2002) 727-739
5. Tatum J.L., and Hoffman J.M. Role of imaging in clinical trials of antiangiogenesis therapy in oncology. Acad Radiol 7 (2000) 798-799
6. Miller J.C., Pien H.H., Sahani D., et al. Imaging angiogenesis: applications and potential for drug development. J Nat Cancer lnst 97 (2005) 172-187
7. Galbraith S.M. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol 76 (2003) s83-s86
8. Provenzale J.M. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 188 (2007) 11-23
9. Gee M.S., Saunders H.M., Lee J.C., et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 61 (2001) 2974-2982
10. Donnelly E.F., Geng L., Wojcicki W.E., et al. Quantified power Doppler US of tumor blood flow correlates with microscopic quantification of tumor blood vessels. Radiology 219 (2001) 166-170
11. Delorme S., Haberkorn U., Kinscherf R., et al. Changes of tumor vascularity during gene therapy monitored with color Doppler US. Ultrasound Med Biol 27 (2001) 1595-1603
12. Iordanescu I., Becker C., Zetter B., et al. Tumor vascularity evaluation in a murine model with contrast-enhanced color Doppler US-effect of angiogenesis inhibitors. Radiology 222 (2002) 460-467
13. Delorme S., Peschke P., Zuna I., et al. Imaging the smallest tumor vessels using color Doppler ultrasound in an experiment [article in German]. Radiologe 41 (2001) 168-172
14. Phillips P., and Gardner E. Contrast-agent detection and quantification. Eur Radiol 14 suppl (2004) 4-10
15. Bleuzen A., and Tranquart F. Incidental liver lesions: diagnostic value of cadence contrast pulse sequencing (CPS) and SonoVue. Eur Radiol 14 (2004) 53-62
16. Wink M.H., de la Rosette J.J., Laguna P., et al. Ultrasonography of renal masses using contrast pulse sequence imaging: a pilot study. J Endourol 21 (2007) 466-472
17. Rissanen T.T., Korpisalo P., Karvinen H., et al. High-resolution ultrasound perfusion imaging of therapeutic angiogenesis. JACC: Cardiovasc Imaging 1 (2008) 83-91
18. Zhu B.D., Yuan S.J., Zhao Q.C., et al. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol 11 (2005) 1382-1386
19. Kumarv V., Abbas A.K., Fausto, and Aater J.C. Robbins and Cotran pathologic basis of disease. 8th ed. (2007), Saunders, Philadelphia
20. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
21. D'Amato R.J., Loughnan M.S., Flynn E., et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91 (1994) 4082-4085
22. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64 (1997) 971-978
23. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7 (2005) E14-E19
24. Rissanen T.T., Korpisalo P., Markkanen J.E., et al. Blood flow remodels growing vasculature during vascular endothelial growth factor gene therapy and determines between capillary arterialization and sprouting angiogenesis. Circulation 112 (2005) 3937-3946
25. Cosgrove D. Angiogenesis imaging ultrasound. Br J Radiol 76 (2003) S43-S49
26. Pollard R.E., Broumas A.R., Wisner E.R., et al. Quantitative contrast enhanced ultrasound and CT assessment of tumor response to antiangiogenic therapy in rats. Ultrasound Med Biol 33 (2007) 235-245
27. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
28. Broumas A.R., Pollard R.E., Bloch S.H., et al. Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow. Invest Radiol 40 (2005) 134-147
29. De Giorgi U., Aliberti C., Benea G., et al. Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 11 (2005) 6171-6176
30. Lassau N., Lamuraglia M., Chami L., et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR Am J Roentgenol 187 (2006) 1267-1273
31. Lamuraglia M., Le Cesne A., Chami L., et al. Dynamic contrast-enhanced Doppler ultrasound (DCE-US) is a useful radiological assessment to early predict the outcome of patients with gastrointestinal stromal tumors (GIST) treated with imatinib (IM) [abstract]. J Clin Oncol 24 (2006) 9539
32. Du G.J., Lin H.H., Xu Q.T., et al. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol 43 (2005) 112-119
33. Kotoh T., Dhar D.K., Masunaga R., et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 125 (1999) 536-544
34. Benjamin R.S., Choi H., Macapinlac H.A., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 (2007) 1760-1764
35. Choi H., Charnsangavej C., Faria S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759